Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Coagulation

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Importance of Antibody Titer Determination to the Effective Use of Convalescent Plasma.

Current topics in microbiology and immunology·2024

Same author

Achieving Diversity Through Decentralization.

Journal of general internal medicine·2024

Same author

HIV risk behavior profiles among men who have sex with men interested in donating blood: Findings from the Assessing Donor Variability and New Concepts in Eligibility study.

Transfusion·2023

Same author

Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.

Vaccine: X·2023

Same author

End of a Declared Public Health Emergency - Implications for U.S. Emergency Use Authorizations.

The New England journal of medicine·2023

Same author

Bivalent Covid-19 Vaccines.

The New England journal of medicine·2023

Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026

Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026

Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026

Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026

Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026

Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Coagulation disorders in the ICU.

Peter W Marks¹

¹Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. peter.marks@yale.edu

Clinics in Chest Medicine

|February 3, 2009

Summary

This summary is machine-generated.

In intensive care units (ICUs), managing bleeding and clotting disorders is crucial. Proper use of blood products and anticoagulants ensures effective treatment while minimizing risks for critically ill patients.

Related Experiment Videos

Last Updated: Jun 26, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Area of Science:

Critical Care Medicine
Hematology
Pharmacology

Background:

Disorders of hemostasis and thrombosis are common in the Intensive Care Unit (ICU).
Interpreting laboratory findings is key for effective patient management.
A range of blood products, hemostatic agents, and anticoagulants are available.

Purpose of the Study:

To review the appropriate use of hemostatic agents and anticoagulants in the ICU.
To emphasize the importance of laboratory findings in guiding therapy.
To outline strategies for maximizing therapeutic benefits and minimizing complications.

Main Methods:

Literature review of hemostasis and thrombosis management in critical care.
Analysis of current guidelines and evidence for blood product and anticoagulant use.
Discussion of clinical scenarios requiring intervention.

Main Results:

Fresh frozen plasma, cryoprecipitate, and other hemostatic agents are most effective when used judiciously.
Indications for use include active bleeding, invasive procedures, and high bleeding risk.
Anticoagulant therapy requires careful consideration of patient-specific factors.

Conclusions:

Optimizing the use of hemostatic agents and anticoagulants is vital in the ICU.
Therapeutic decisions should be based on active bleeding, procedural needs, and bleeding risk assessment.
Effective management balances the need for intervention with the potential for complications.